Type I IFN family members: Similarity, differences and interaction

Cytokine and Growth Factor Reviews

Volumn 26, Issue 2, 2015, Pages 103-111

  Capobianchi, Maria Rosaria ^a   Uleri, Elena ^b   Caglioti, Claudia ^a   Dolei, Antonina ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Anti interferon strategies; Interferon genes and receptors; Interferon types I III; Interferon interferon interactions

Indexed keywords

ADAPTOR PROTEIN; ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON PROMOTER STIMULATING FACTOR 1 PROTEIN; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR; INTERFERON TYPE III; INTERLEUKIN 10; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 24; INTERLEUKIN 26; JANUS KINASE; PEGINTERFERON; STAT PROTEIN; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; ANTIVIRUS AGENT;

ANTIGEN PRESENTATION; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOPHAGY; BINDING AFFINITY; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; CELL DIFFERENTIATION; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; INFECTION PREVENTION; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON ALPHA GENE; INTERFERON BETA GENE; INTERFERON GAMMA GENE; INTERFERON PRODUCTION; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; RECEPTOR BINDING; SARCOIDOSIS; SIGNAL TRANSDUCTION; SPONTANEOUS ABORTION; THYROID DISEASE; TUMOR IMMUNITY; UPREGULATION; VIRAL CLEARANCE; VIRUS INHIBITION; VIRUS REPLICATION; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION; VIROLOGY; VIRUS INFECTION;

ANTIVIRAL AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENETIC VARIATION; HUMANS; INTERFERON TYPE I; INTERFERON-GAMMA; INTERFERONS; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; VIRUS DISEASES;

EID: 84926462900     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.10.011     Document Type: Article

References (100)

1. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957, 147:258-267.
2. Nagano Y., Kojima Y. Inhibition of vaccinia infection by a liquid factor in tissues infected by homologous virus. C R Seances Soc Biol Fil 1958, 152:1627-1629.
3. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev 2001, 14:778-809.
4. Touzot M., Soumelis V., Asselah T. A dive into the complexity of type I interferon antiviral functions. J Hepatol 2012, 56:726-728.
5. Wheelock E.F. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965, 149:310-311.
6. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4:69-77.
7. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4:63-68.
8. Donnelly R.P., Kotenko S.V. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010, 30:555-564.
9. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat Rev Immunol 2014, 14:36-49.
10. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004, 202:8-32.
11. Schmeisser H., Bekisz J., Zoon K.C. New function of type I IFN: induction of autophagy. J Interferon Cytokine Res 2014, 34:71-78.
12. Lopušná K., Režuchová I., Betáková T., Skovranová L., Tomašková J., Lukáčiková L., et al. Interferons lambda, new cytokines with antiviral activity. Acta Virol 2013, 57:171-179.
13. Le Bon A., Tough D.F. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002, 14:432-436.
14. Kotenko S.V. The family of IL-10-related cytokines and their receptors: related, but to what extent. Cytokine Growth Factor Rev 2002, 13:223-240.
15. Renauld J.C. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol 2003, 3:667-676.
16. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979.
17. Kotenko S.V., Langer J.A. Full house: 12 receptors for 27 cytokines. Int Immunopharmacol 2004, 4:593-608.
18. Zhang S.Y., Boisson-Dupuis S., Chapgier A., Yang K., Bustamante J., Puel A., et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008, 226:29-40.
19. Jouanguy E., Zhang S.Y., Chapgier A., Sancho-Shimizu V., Puel A., et al. Human primary immunodeficiencies of type I interferons. Biochimie 2007, 89:878-883.
20. Newport M.J., Huxley C.M., Huston S., Hawrylowicz C.M., Oostra B.A., Williamson R., et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996, 335:1941-1949.
21. Jouanguy E., Altare F., Lamhamedi S., Revy P., Emile J.F., Newport M., et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med 1996, 335:1956-1961.
22. Smith N.L., Denning D.W. Clinical implications of interferon gamma genetic and epigenetic variants. Immunology 2014, Accepted Article. 10.1111/imm.12362.
23. Devasthanam A.S. Mechanisms underlying the inhibition of interferon signaling by viruses. Virulence 2014, 5:270-277.
24. van Montfoort N., Olagnier D., Hiscott J. Unmasking immune sensing of retroviruses: interplay between innate sensors and host effectors. Cytokine Growth Factor Rev 2014, pii:S1359-6101(14)00089-6.
25. Orzalli M.H., Knipe D.M. Cellular sensing of viral DNA and viral evasion mechanisms. Annu Rev Microbiol 2014, 68:477-492.
26. Haller O., Kochs G., Weber F. Interferon, Mx, and viral countermeasures. Cytokine Growth Factor Rev 2007, 18:425-433.
27. Chiang J.J., Davis M.E., Gack M.U. Regulation of RIG-I-like receptor signaling by host and viral proteins. Cytokine Growth Factor Rev 2014, pii:S1359-6101(14)00059-8.
28. Ronco L.V., Karpova A.Y., Vidal M., Howley P.M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998, 12:2061-2072.
29. Wong G., Kobinger G.P., Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol 2014, 10:781-790.
30. Horvath C.M. The Jak-STAT pathway stimulated by interferon alpha or interferon beta. Sci STKE 2004, 2004:tr10.
31. Stark G.R., Kerr I.M. Interferon-dependent signaling pathways: DNA elements, transcription factors, mutations, and effects of viral proteins. J Interferon Res 1992, 12:147-151.
32. Yokota S., Saito H., Kubota T., Yokosawa N., Amano K., Fujii N. Measles virus suppresses interferon-alpha signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-alpha receptor complex. Virology 2003, 306:135-146.
33. Xu W., Edwards M.R., Borek D.M., Feagins A.R., Mittal A., Alinger J.B., et al. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 2014, 16:187-200.
34. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003, 17:488-490.
35. Li Z., Okonski K.M., Samuel C.E. Adenosine deaminase acting on RNA 1 (ADAR1) suppresses the induction of interferon by measles virus. J Virol 2012, 86:3787-3794.
36. Kawahara Y., Zinshteyn B., Sethupathy P., Iizasa H., Hatzigeorgiou A.G., Nishikura K. Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science 2007, 315:1137-1140.
37. Smith G.L., Benfield C.T., Maluquer de Motes C., Mazzon M., Ember S.W., Ferguson B.J., et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol 2013, 94:2367-2392.
38. Huang J., Smirnov S.V., Lewis-Antes A., Balan M., Li W., Tang S., et al. Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci U S A 2007, 104:9822-9827.
39. Brady G., Bowie A.G. Innate immune activation of NFκB and its antagonism by poxviruses. Cytokine Growth Factor Rev 2014, pii:S1359-6101(14)00066-5.
40. Puehler F., Schwarz H., Waidner B., Kalinowski J., Kaspers B., Bereswill S., et al. An interferon-gamma-binding protein of novel structure encoded by the fowlpox virus. J Biol Chem 2003, 278:6905-6911.
41. Perdiguero B., Esteban M. The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 2009, 29:581-598.
42. Silva L.C., Almeida G.M., Oliveira D.B., Dornas F.P., Campos R.K., La Scola B., et al. A resourceful giant: APMV is able to interfere with the human type I interferon system. Microbes Infect 2014, 16:187-195.
43. Fleischmann W.R, Georgiades J.A., Osborne L.C., Johnson H.M. Potentiation of interferon activity by mixed preparations of fibroblast and immune interferon. Infect Immun 1979, 26:248-253.
44. De Clercq E., Zhang Z.X., Huygen K. Synergism in the antitumor effects of type 1 and type II interferon in mice inoculated with leukemia L1210 cells. Cancer Lett 1982, 15:223-228.
45. Capobianchi M.R., Mattana P., Mercuri F., Conciatori G., Ameglio F., Ankel H., et al. Acid lability is not an intrinsic property of interferon-alpha induced by HIV-infected cells. J Interferon Res 1992, 12:431-438.
46. Sainz B., Halford W.P. Alpha/beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol 2002, 76:11541-11550.
47. Sainz B., LaMarca H.L., Garry R.F., Morris C.A. Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. Virol J 2005, 2:14.
48. Larkin J., Jin L., Farmen M., Venable D., Huang Y., Tan S.L., et al. Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J Interferon Cytokine Res 2003, 23:247-257.
49. Asper M., Sternsdorf T., Hass M., Drosten C., Rhode A., Schmitz H., et al. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol 2004, 78:3162-3169.
50. Desloges N., Rahaus M., Wolff M.H. Role of the protein kinase PKR in the inhibition of varicella-zoster virus replication by beta interferon and gamma interferon. J Gen Virol 2005, 86:1-6.
51. Castilletti C., Bordi L., Lalle E., Rozera G., Poccia F., Agrati C., et al. Coordinate induction of IFN-alpha and -gamma by SARS-CoV also in the absence of virus replication. Virology 2005, 341:163-169.
52. Scagnolari C., Trombetti S., Alberelli A., Cicetti S., Bellarosa D., Longo R., et al. The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins. Intervirology 2007, 50:156-160.
53. Peng T., Zhu J., Hwangbo Y., Corey L., Bumgarner R.E. Independent and cooperative antiviral actions of beta interferon and gamma interferon against herpes simplex virus replication in primary human fibroblasts. J Virol 2008, 82:1934-1945.
54. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E.S., Kotenko S.V., MacDonald M.R., et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887-1898.
55. Shindo H., Maekawa S., Komase K., Miura M., Kadokura M., Sueki R., et al. IL-28B (IFN-λ3) and IFN-α synergistically inhibit HCV replication. J Viral Hepat 2013, 20:281-289.
56. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006, 80:4501-4509.
57. François-Newton V., Magno de Freitas Almeida G., Payelle-Brogard B., Monneron D., Pichard-Garcia L., Piehler J., et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLoS ONE 2011, 6:e22200.
58. Bordi L., Lalle E., Lapa D., Caglioti C., Quartu S., Capobianchi M.R., et al. Type III interferon (IFN-lambda) antagonizes the antiviral activity of interferon-alpha in vitro. J Biol Regul Homeost Agents 2013, 27:1001-1009.
59. Gresser I. Antitumor effects of interferon. Adv Cancer Res 1972, 16:97-140.
60. Rusinova I., Forster S., Yu S., Kannan A., Masse M., Cumming H., et al. INTERFEROME v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res 2013, 41(database issue):D1040-D1046.
61. Wijesundara D.K., Xi Y., Ranasinghe C. Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design. Front Immunol 2014, 5:412.
62. El-Baky N.A., Redwan E.M. Therapeutic alpha-interferons protein: structure production, and biosimilar. Prep Biochem Biotechnol 2015, 45:109-127.
63. Swetly P., Ostertag W. Friend virus release and induction of haemoglobin synthesis in erythroleukaemic cells respond differently to interferon. Nature 1974, 251:642-644.
64. Rossi G.B., Dolei A., Cioé L., Benedetto A., Matarese G.P., Belardelli F. Inhibition of transcription and translation of globin messenger RNA in dimethyl sulfoxide-stimulated Friend erythroleukemic cells treated with interferon. Proc Natl Acad Sci USA 1977, 74:2036-2040.
65. Axtell R.C., Raman C. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 2012, 248:23-35.
66. Li Q., Kawamura K., Tada Y., Shimada H., Hiroshima K., Tagawa M. Novel type III interferons produce anti-tumor effects through multiple functions. Front Biosci (Landmark Ed) 2013, 18:909-918.
67. Ismail A., Yusuf N. Type I interferons: key players in normal skin and select cutaneous malignancies. Dermatol Res Pract 2014, 2014:847545.
68. Balachandran S., Adams G.P. Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective. J Interferon Cytokine Res 2013, 33:171-180.
69. Jaitin D.A., Roisman L.C., Jaks E., Gavutis M., Piehler J., Van der Heyden J., et al. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 2006, 26:1888-1897.
70. Levin D., Schneider W.M., Hoffmann H.H., Yarden G., Busetto A.G., Manor O., et al. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci Signal 2014, 7:ra50.
71. Ambjørn M., Ejlerskov P., Liu Y., Lees M., Jaatela M., Issazadeh-Navikas S. IFNbeta1/interferon-beta-induced autophagy in MCF-7 breast cancer cells counteracts its proapoptotic function. Autophagy 2013, 9:287-302.
72. Gade P., Manjegowda S.B., Nallar S.C., Maachani U.B., Cross A.S., Kalvakolanu D.V. Regulation of the death-associated protein kinase 1 expression and autophagy via ATF6 requires apoptosis signal-regulating kinase 1. Mol Cell Biol 2014, 34:4033-4048.
73. de Bruin A.M., Voermans C., Nolte M.A. Impact of interferon-γ on hematopoiesis. Blood 2014, pii:blood-2014-04-568451.
74. Cioé L., O'Brien T.G., Diamond L. Inhibition of adipose conversion of BALB/c 3T3 cells by interferon and 12-O-tetradecanoylphorbol-13-acetate. Cell Biol Int Rep 1980, 4:255-264.
75. Vidal C., Bermeo S., Li W., Huang D., Kremer R., Duque G. Interferon gamma inhibits adipogenesis in vitro and prevents marrow fat infiltration in oophorectomized mice. Stem Cells 2012, 30:1042-1048.
76. Russo E., Salzano M., Postiglione L., Guerra A., Marotta V., Vitale M. Interferon-γ inhibits integrin-mediated extracellular signal-regulated kinase activation stimulated by fibronectin binding in thyroid cells. J Endocrinol Invest 2013, 36:375-378.
77. Bekisz J., Sato Y., Johnson C., Husain S.R., Puri R.K., Zoon K.C. Immunomodulatory effects of interferons in malignancies. J Interferon Cytokine Res 2013, 33:154-161.
78. Garcin G., Bordat Y., Chuchana P., Monneron D., Law H.K., Piehler J., et al. Differential activity of type I interferon subtypes for dendritic cell differentiation. PLOS ONE 2013, 8:e58465.
79. Heron I., Hokland M., Berg K. Enhanced expression of β2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 1978, 75:6215-6219.
80. Dolei A., Ameglio F., Capobianchi M.R., Tosi R. Human β-type interferon enhances the expression and shedding of Ia-like antigens. Comparison to HLA-A, B, C and β2-microglobulin. Antiviral Res 1981, 1:367-381.
81. Mennechet F.J., Uzé G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006, 107:4417-4423.
82. Dolei A., Capobianchi M.R., Ameglio F. Human interferon-gamma enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-alpha and interferon-beta. Infect Immun 1983, 40:172-176.
83. Barna B.P., Chou S.M., Jacobs B., Yen-Lieberman B., Ransohoff R.M. Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol 1989, 23:45-53.
84. Capobianchi M.R., Serra C., Abbate I., Marongiu P., Castilletti C., Tilocca F., et al. Treatment of HIV-infected fibroblasts with human leukocyte antigen (HLA)-DR-inductive cytokines leads to infectious virions with newly acquired HLA-DR. AIDS 1994, 8:1731-1733.
85. Serra C., Biolchini A., Mei A., Kotenko S., Dolei A. Type III and I interferons increase HIV uptake and replication in human cells that overexpress CD4, CCR5, and CXCR4. AIDS Res Hum Retroviruses 2008, 24:173-180.
86. de Kleijn S., Langereis J.D., Leentjens J., Kox M., Netea M.G., Koenderman L., et al. IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLOS ONE 2013, 8:e72249.
87. Beiting D.P. Protozoan parasites and type I interferons: a cold case reopened. Trends Parasitol 2014, 30:491-498.
88. Hellesen A., Edvardsen K., Breivik L., Husebye E.S., Bratland E. The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease. Clin Exp Immunol 2014, 176:351-362.
89. Micallef A., Grech N., Farrugia F., Schembri-Wismayer P., Calleja-Agius J. The role of interferons in early pregnancy. Gynecol Endocrinol 2014, 30:1-6.
90. Panarina M., Kisand K., Alnek K., Heilman K., Peet A., Uibo R. Interferon and interferon-inducible gene activation in patients with type 1 diabetes. Scand J Immunol 2014, 80:283-292.
91. Buss G., Cattin V., Spring P., Malinverni R., Gilliet M. Two cases of interferon-alpha-induced sarcoidosis Koebnerized along venous drainage lines: new pathogenic insights and review of the literature of interferon-induced sarcoidosis. Dermatology 2013, 226:289-297.
92. Burman P., Karlsson F.A., Öberg K., Alm G., Orava M., Vihko R. Autoimmune thyroid disease in interferon-treated patients. Lancet 1985, 2:100-101.
93. Akeno N., Smith E.P., Stefan M., Huber A.K., Zhang W., Keddache M., et al. IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol 2011, 186:4693-4706.
94. Reder A.T., Feng X. How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J Interferon Cytokine Res 2014, 34:589-599.
95. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
96. Rynda A., Maddaloni M., Ochoa-Repáraz J., Callis G., Pascual D.W. IL-28 supplants requirement for T(reg) cells in protein sigma1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE). PLoS ONE 2010, 5:e8720.
97. Hoyo-Becerra C., Schlaak J.F., Hermann D.M. Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun 2014, pii:S0889-1591(14)00365-1.
98. Nomura H., Miyagi Y., Tanimoto H., Yamashita N., Oohashi S., Nishiura S. Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin. Hepatol Res 2012, 42:241-247.
99. Zheng L.S., Hitoshi S., Kaneko N., Takao K., Miyakawa T., Tanaka Y., et al. Mechanisms for interferon-α-induced depression and neural stem cell dysfunction. Stem Cell Rep 2014, 3:73-84.
100. Campos A.C., Vaz G.N., Saito V.M., Teixeira A.L. Further evidence for the role of interferon-gamma on anxiety- and depressive-like behaviors: involvement of hippocampal neurogenesis and NGF production. Neurosci Lett 2014, 578:100-105.